| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 4.098 | 3.762 | 6.753 | 3.711 | 843 | 31 | 30 | 30 | 0 | 30 |
| Total Income - EUR | 4.098 | 3.762 | 6.753 | 3.711 | 843 | 31 | 30 | 30 | 0 | 30 |
| Total Expenses - EUR | 2.753 | 2.122 | 3.056 | 975 | 317 | 609 | 875 | 3.048 | 3.092 | 560 |
| Gross Profit/Loss - EUR | 1.346 | 1.641 | 3.698 | 2.737 | 526 | -578 | -845 | -3.017 | -3.092 | -530 |
| Net Profit/Loss - EUR | 1.222 | 1.528 | 3.495 | 2.625 | 501 | -579 | -846 | -3.018 | -3.092 | -530 |
| Employees | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Bio Consulting Rar S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 1.522 | 3.033 | 6.590 | 8.848 | 6.749 | 5.940 | 5.003 | 2.508 | 13 | 15 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 832 | 0 | 6.743 | 5.929 | 4.993 | 2.468 | 0 | 0 |
| Cash | 1.522 | 3.033 | 5.758 | 8.848 | 5 | 11 | 10 | 40 | 13 | 15 |
| Shareholders Funds | 1.351 | 2.865 | 6.311 | 8.821 | 6.622 | 5.918 | 4.941 | 1.939 | -1.159 | -1.683 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 171 | 168 | 278 | 27 | 126 | 22 | 62 | 570 | 1.172 | 1.698 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7211
|
|||||||||
Comments - Bio Consulting Rar S.r.l.